Revelation Biosciences (REVB) Competitors $3.08 +0.08 (+2.67%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.02 -0.06 (-1.98%) As of 04/17/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock REVB vs. ATHA, NERV, TRIB, FLGC, BCDA, CSCI, AFMD, BMRA, CTXR, and GOVXShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Athira Pharma (ATHA), Minerva Neurosciences (NERV), Trinity Biotech (TRIB), Flora Growth (FLGC), BioCardia (BCDA), COSCIENS Biopharma (CSCI), Affimed (AFMD), Biomerica (BMRA), Citius Pharmaceuticals (CTXR), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Athira Pharma Minerva Neurosciences Trinity Biotech Flora Growth BioCardia COSCIENS Biopharma Affimed Biomerica Citius Pharmaceuticals GeoVax Labs Athira Pharma (NASDAQ:ATHA) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk. Which has better valuation and earnings, ATHA or REVB? Athira Pharma is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAthira PharmaN/AN/A-$117.67M-$2.53-0.09Revelation BiosciencesN/AN/A-$120K-$139.86-0.02 Do analysts rate ATHA or REVB? Athira Pharma currently has a consensus target price of $13.83, indicating a potential upside of 5,663.89%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ATHA or REVB? In the previous week, Athira Pharma and Athira Pharma both had 1 articles in the media. Athira Pharma's average media sentiment score of 0.00 beat Revelation Biosciences' score of -1.00 indicating that Athira Pharma is being referred to more favorably in the media. Company Overall Sentiment Athira Pharma Neutral Revelation Biosciences Negative Does the MarketBeat Community believe in ATHA or REVB? Revelation Biosciences received 10 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 63.83% of users gave Revelation Biosciences an outperform vote while only 54.05% of users gave Athira Pharma an outperform vote. CompanyUnderperformOutperformAthira PharmaOutperform Votes2054.05% Underperform Votes1745.95% Revelation BiosciencesOutperform Votes3063.83% Underperform Votes1736.17% Which has more risk & volatility, ATHA or REVB? Athira Pharma has a beta of 3.05, suggesting that its stock price is 205% more volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Is ATHA or REVB more profitable? Athira Pharma's return on equity of -115.62% beat Revelation Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Athira PharmaN/A -115.62% -88.94% Revelation Biosciences N/A -193.51%-84.00% Do institutionals and insiders hold more shares of ATHA or REVB? 57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by company insiders. Comparatively, 0.1% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAthira Pharma beats Revelation Biosciences on 8 of the 13 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.79M$6.46B$5.31B$7.35BDividend YieldN/A3.21%5.45%4.34%P/E Ratio-0.016.9521.9417.82Price / SalesN/A231.01380.6697.73Price / CashN/A65.6738.2534.64Price / Book0.015.936.453.98Net Income-$120,000.00$143.22M$3.22B$247.81M7 Day Performance-11.49%1.11%0.74%0.28%1 Month Performance8.45%-13.21%-9.66%-7.60%1 Year Performance-91.41%-8.51%11.81%1.49% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.4414 of 5 stars$3.08+2.7%N/A-91.4%$2.79MN/A-0.0110Negative NewsATHAAthira Pharma2.0275 of 5 stars$0.25-0.5%$13.83+5,462.3%-88.7%$9.71MN/A-0.0940NERVMinerva Neurosciences2.8145 of 5 stars$1.38+0.8%$5.00+262.1%-35.5%$9.66MN/A-3.149Analyst ForecastShort Interest ↑Gap UpTRIBTrinity Biotech0.7833 of 5 stars$0.53-1.9%N/A-69.5%$9.57M$59.13M-0.23480Gap DownFLGCFlora Growth1.9539 of 5 stars$0.48-2.2%$5.00+941.7%-65.5%$9.33M$59.51M-0.36280Gap UpBCDABioCardia2.8725 of 5 stars$1.99-1.0%$25.00+1,156.3%-64.4%$9.31M$58,000.00-0.4840CSCICOSCIENS BiopharmaN/A$2.44-4.7%N/AN/A$9.21M$7.60M-0.2120AFMDAffimed3.5107 of 5 stars$0.57flat$13.50+2,268.0%-85.8%$9.18M$877,000.000.00200Analyst ForecastNews CoverageGap UpBMRABiomerica0.2297 of 5 stars$0.50-0.4%N/A-91.8%$9.13M$5.58M-1.4660Earnings ReportStock SplitGap DownCTXRCitius Pharmaceuticals2.2532 of 5 stars$1.05+3.4%$54.50+5,090.5%-94.9%$9.02MN/A0.0020Short Interest ↑GOVXGeoVax Labs2.2887 of 5 stars$0.95-6.7%$14.20+1,391.4%-44.7%$8.98M$3.95M-0.1710Analyst ForecastShort Interest ↑Analyst RevisionNews Coverage Related Companies and Tools Related Companies Athira Pharma Competitors Minerva Neurosciences Competitors Trinity Biotech Competitors Flora Growth Competitors BioCardia Competitors COSCIENS Biopharma Competitors Affimed Competitors Biomerica Competitors Citius Pharmaceuticals Competitors GeoVax Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REVB) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy REVB Stock Free REVB Stock Alerts